Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb 5;33(3):153.
doi: 10.1007/s00520-024-09135-5.

Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review

Loredana Amoroso  1   2 , Franca Fagioli  3 , Annalisa Tondo  4 , Massimo Conte  5 , Clara Badino  5 , Andrea Di Cataldo  6 , Elisabetta Viscardi  7 , Francesco De Leonardis  8 , Maria Antonietta De Ioris  9 , Roberto Luksch  10
Affiliations
Review

Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review

Loredana Amoroso et al. Support Care Cancer. .

Abstract

Purpose: Patients with high-risk neuroblastoma (HR NB) frequently present with metastases in the bone marrow and bone. Approximately 15% of these patients are refractory to induction therapy, and 50% relapse. Dinutuximab beta is an anti-GD2 monoclonal antibody approved in Europe for maintenance therapy of pediatric patients with HR NB. Immunotherapy with anti-GD2 antibodies improves the survival of children with HR NB and relapsed or refractory disease. It is associated with adverse events, such as pain, fever, allergic reactions, capillary leak syndrome, and diarrhea. This manuscript aims to propose a practical guide in support and prevention treatment of adverse events.

Methods: MEDLINE was searched using the terms "GD2," "ch14.18/CHO," "anti-GD2 antibody," "dinutuximab beta," and "neuroblastoma." The experts reappraised available evidence discussing different clinical Italian experiences.

Results: Neuropathic pain is the main toxicity associated with dinutuximab beta and can be prevented with analgesics, including intravenous opioids and gabapentin by mouth. The intensity of the supportive treatment decreases from course to course.

Conclusion: In the experience of the authors, adverse events associated with dinutuximab beta may be prevented and managed in experienced centers. The supportive therapy may be reduced after the first cycle to improve the quality of life.

Keywords: Anti-GD2; Dinutuximab beta; Neuroblastoma; Pediatrics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: N/A. Consent for publication: N/A. Competing interests: The authors were consultants on a board for EUSA Pharma/Recordati Rare Diseases.

References

    1. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL (2014) Declining childhood and adolescent cancer mortality. Cancer 120:2497–2506. https://doi.org/10.1002/cncr.28748 - DOI - PubMed
    1. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078. https://doi.org/10.1038/nrdp.2016.78 - DOI - PubMed
    1. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer group. N Engl J Med 341:1165–1173. https://doi.org/10.1056/NEJM199910143411601 - DOI - PubMed
    1. Amoroso L, Haupt R, Garaventa A, Ponzoni M (2017) Investigational drugs in phase II clinical trials for the treatment of neuroblastoma. Expert Opin Investig Drugs 26:1281–1293. https://doi.org/10.1080/13543784.2017.1380625 - DOI - PubMed
    1. Suzuki M, Cheung NK (2015) Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 19:349–362. https://doi.org/10.1517/14728222.2014.986459 - DOI - PubMed

MeSH terms

LinkOut - more resources